Global Cardiac Restoration Systems Market - 2022-2029

Global Cardiac Restoration Systems Market - 2022-2029

Market Overview

The global cardiac restoration systems size was valued at US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of XX% during the forecast period (2022-2029).

Cardiac restoration systems are employed for treating damaged and diseased heart valves. CVDs affect the heart and blood vessels, escalating conditions such as coronary heart diseases, stroke, etc., causing high-risk blood clots and fatty depositions in arteries. Cardiac restoration systems are used after any coronary artery bypass grafting remodeling the ventricular and initiating surgical anterior ventricular endocardial restoration (SAVER).

Market Dynamics

The growing number of cardiac diseases, geriatric population, market developments, and obese population is boosting the global cardiac restoration systems market.

The increasing number of cardiovascular disease cases is fueling the growth of the global cardiac restoration systems market.

Cardiovascular diseases include heart and blood vessel ailments, including coronary heart disorder, cerebrovascular disease, rheumatic heart disease, and other conditions. The growing cases of CVD are driving the global cardiac restoration systems. For instance, according to the American Heart Association, roughly 19.1 million deaths were caused by CVD globally in 2020. Globally, it was assessed that about 244.1 million individuals were living with ischemic heart disease (IHD), and it was more prevalent in males than in females (141.0 and 103.1 million people, respectively) in 2020. Also, according to the WHO, Cardiovascular diseases (CVDs) are the major cause of death worldwide, causing an estimated 17.9 million deaths annually.

The most important behavioral risk elements of heart disease and stroke are an unhealthful diet, physical laziness, tobacco use, and the harmful use of alcohol. The effects of behavioral risk factors may appear in patients as increased blood pressure, boosted blood glucose, extended blood lipids, and overweight and obesity. The upsurge in behavioral risk factors leads to increased CVDs globally. According to the American Heart Association's 2022 Heart Disease & Stroke Statistical Update Fact Sheet Global Burden of Disease, Tobacco (including smoking, secondhand smoke, and chewing tobacco) caused an estimated 8.1 million deaths globally in 2020 (6.3 million men and 1.8 million women). Also, based on 2020 data, age-standardized mortality rates attributable to high body mass index were lowest in high-income Asia Pacific and highest in Oceania, North Africa, the Middle East, Central Asia, southern sub-Saharan Africa, and locations in Central and Eastern Europe, Central sub-Saharan Africa, and Central Latin America. High BMI was attributed to 2.40 million global deaths in 2020.

Likewise, according to PAHO, globally, alcohol consumption contributes to 3 million deaths each year, and several millions of people lose health. The consumption of alcohol is causally linked to over 200 health conditions, including liver diseases, road injuries, violence, several types of cancers, cardiovascular diseases, suicides, tuberculosis, and HIV/AIDS. Thus, the mentioned data indicates that the increase in behavioral risk factors is leading to rising in cardiovascular diseases, thereby boosting the global cardiac restoration systems market growth in the forecast period.

The high cost of cardiac surgery will hamper the global cardiac restoration systems market growth.

However, the high cost of cardiac surgery is restraining the global cardiac restoration systems market during the forecast period. For example, the average tricuspid valve repair surgery cost in India is about 3900 USD.

COVID-19 Impact Analysis

According to a Cardiac surgery practice during the COVID-19 outbreak: a regionwide survey article published in January 2021 by the Journal of Thoracic Disease, all healthcare centers adopted specific protocols for screening patients and personnel. A significant reduction in the number of dedicated intensive care unit (ICU) beds was reduced by around 30.0%, and cardiac operating rooms were reduced by approximately 22.2%along with personnel relocation to other departments was disclosed such as anesthesiologists by 5.8%, perfusionists by 5.6%, and nurses by 4.8% among others. Cardiac surgeons were never reallocated to other services. Globally, we witnessed dramatically lower adult cardiac surgery case volumes, with 335 procedures in 2020 compared to over 667 procedures in 2019, as institutions and surgeons followed guidelines to curtail non-urgent operations. Thus, the reduction in cardiac procedures and relocation of resources toward urgent healthcare requirements hampered the market growth, negatively impacting the global cardiac restoration system market.

Segment Analysis

Mitral valve restoration systems are estimated to grow at the fastest CAGR during the forecast period (2022-2029).

The prevalence of rheumatic heart disease, the most common valvular heart disease (affecting approximately 41 million people), has been rising in developing nations, likely due to the expansion of the young adult population and the decrease in premature mortality that has resulted from improved access to antibiotics, microbiological testing, and echocardiography. Mitral regurgitation affects 24 million people worldwide, with great variability between and among nations. Primary mitral regurgitation arises due to myxomatous degeneration and mitral valve prolapse, largely due to genetic predispositions, while secondary mitral regurgitation accounts for 65% of cases and arises secondary to dilation and heart failure. MR is either equally prevalent between the sexes or slightly more prevalent in men than women. Mitral valve prolapse rates (MVP) are considerably higher in white patients than in black patients. MVP is the most common cardiac mitral valvular pathology worldwide, accounting for 2% to 3% of the total population. RHD remains prevalent in developing countries and is the most common cause of mitral valvular pathology resulting in hospital admissions. Acute MR can present with sudden onset of dyspnea and flash pulmonary edema, frequently secondary to myocardial infarction.

Chronic MR is often asymptomatic, though treatment is recommended before symptom onset. Furthermore, developments such as the first beating heart mitral valve repair on the West Coast were performed by Tom C. Nguyen, MD, chief of UC San Francisco’s Division of Adult Cardiothoracic Surgery, and his surgical team in September 2021. The HARPOON™ Beating Heart Mitral Valve Repair System was used for the procedure as part of the RESTORE clinical trial. Thus, the mentioned data indicates that the mitral valve restoration systems will dominate the global cardiac restoration system in the forecasted period.

Geographical Analysis

The North American market is expected to grow at a high CAGR during the forecast period.

North America is estimated to hold a large market over the forecast period (2022-2029) because of the growing cases of cardiovascular conditions and the existence of key market players in this region. For instance, according to the CDC, a U.S. American dies every 34 seconds because of cardiovascular disease. Cardiovascular disease caused over 697,000 deaths in 2020. Moreover, the existence of key market players such as Abbott, BioVentrix Inc., CryoLife Inc., Edwards Lifesciences Corp, NeoChord Inc. among more, holding most of the global market, endure the growth of North America's cardiac restoration system market at a high CAGR throughout the forecast period. For instance, in March 2020, BioVentrix, Inc., developer of the first transcatheter device for left ventricular remodeling after a heart attack, reported that Ralph Stephan von Bardeleben, MD, of the University Medical Center of Mainz (Germany) has united with the European REVIVE-HF clinical trial of the Revivent TC Transcatheter Ventricular Enhancement System as co-principal investigator. Also, in January 2022, BioVentrix, Inc., a privately held medical device corporation concentrated on less intrusive treatments to treat the left ventricle (LV), known to be the root cause of congestive heart failure (CHF), acquired MateraCor, Inc., a firm focused on preventing the advancement of, and reversing, heart failure through the use of injectable alginate-based hydrogel.

Likewise, in February 2020, CryoLife, Inc., a leading cardiac and vascular surgery company focused on aortic disease, was granted CE Mark for its On-X Ascending Aortic Prosthesis (AAP) indicated for the treatment of diseased, damaged, or malfunctioning native or prosthetic heart valves in the aortic position involving an ascending aortic aneurysm, permitting it to resume dispersal in the European Union. Moreover, in September 2022, Edwards Lifesciences Corporation received FDA approval for its PASCAL Precision transcatheter valve repair system for transcatheter edge-to-edge repair (TEER) in treating patients with degenerative mitral regurgitation (DMR). Thus, the data mentioned indicate that North America's market will grow at a high CAGR throughout the forecasted period.

Competitive Landscape

The growing focus on innovation keeps the global cardiac restoration systems market competitive. Abbott, BioVentrix Inc., NeoChord Inc., Edwards Lifesciences Corp, Virbac, Medtronic Inc., Micro Port Scientific Corporation, CryoLife Inc., Xeltis AG, and Cook Medical are examples of a few key market players. These key players hold the market through acquisitions, product launches, and collaborations. For instance, in March 2022, Edwards Lifesciences received permission from the U.S. Food and Drug Administration (FDA) for the MITRIS RESILIA valve, a tissue valve replacement designed for the heart's mitral position.

Medtronic, Plc.

Overview:

Medtronic plc is Ireland based American medical device company. Medtronic was founded in 1949 and is headquartered in Minneapolis, Minnesota, United States. Medtronics deals with four different businesses: the Minimally Invasive Therapies Group, the Diabetes Group, the Restorative Therapies Group, and the Cardiac and Vascular Group.

Product Portfolio:

The product portfolio of Medtronic, Plc. has CG Future Annuloplasty Ring and Band: The CG Future is an annuloplasty system for mitral valve repair, developed to predictably renovate the annulus to keep the apposition of the anterior and posterior leaflets.

The global cardiac restoration systems market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.